Howard I Scher

Howard I Scher

UNVERIFIED PROFILE

Are you Howard I Scher?   Register this Author

Register author
Howard I Scher

Howard I Scher

Publications by authors named "Howard I Scher"

Are you Howard I Scher?   Register this Author

100Publications

3884Reads

38Profile Views

PTEN loss with ERG-Negative Status is Associated with Lethal Disease after Radical Prostatectomy.

J Urol 2019 Sep 10:101097JU0000000000000533. Epub 2019 Sep 10.

Department of Urology, Johns Hopkins University School of Medicine.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JU.0000000000000533DOI Listing
September 2019

Reply to L. Dirix, B. De Laere et al, and A. Sharp et al.

J Clin Oncol 2019 Aug 2;37(24):2184-2186. Epub 2019 Jul 2.

Andrew J. Armstrong, MD, ScM and Susan Halabi, PhD, Duke University, Durham, NC; Jun Luo, PhD, Johns Hopkins University, Baltimore, MD; David M. Nanus, MD, Weill Cornell Medical College, New York, NY; Howard I. Scher, MD, Memorial Sloan Kettering Cancer Center, New York, NY; Emmanuel S. Antonarakis, MD, Johns Hopkins University, Baltimore, MD; and Daniel J. George, MD, Duke University, Durham, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.01230DOI Listing
August 2019

The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression.

Cancer Cell 2019 Aug 18;36(2):139-155.e10. Epub 2019 Jul 18.

Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Unit 1906, PO Box 301429, Houston, TX 77054/77030-1429, USA; Department of Genitourinary Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2019.06.009DOI Listing
August 2019

Effect of Preanalytic Variables on an Automated PTEN Immunohistochemistry Assay for Prostate Cancer.

Arch Pathol Lab Med 2019 Mar 8;143(3):338-348. Epub 2018 Oct 8.

From the Departments of Pathology (Drs Guedes, Morais, Fedor, Hicks, Gurel, De Marzo, and Lotan), Oncology (Drs Trock, De Marzo, and Lotan), and Urology (Drs Trock and De Marzo), Johns Hopkins University School of Medicine, Baltimore, Maryland; the Department of Pathology, New York University School of Medicine, New York, New York (Drs Melamed and Lee); the Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York (Drs Gopalan and Fine); the Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, California (Dr Knudsen); the Department of Pathology, University of Washington, Seattle (Dr True); and Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York (Dr Scher).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2018-0068-OADOI Listing
March 2019

Improving the Nuclear-Localized Androgen Receptor Splice Variant 7 Test-In Reply.

JAMA Oncol 2019 Mar;5(3):434

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jam
Publisher Site
http://dx.doi.org/10.1001/jamaoncol.2018.6686DOI Listing
March 2019

Circulating Tumor Cells in Prostate Cancer: From Discovery to Clinical Utility.

Clin Chem 2019 Jan;65(1):87-99

Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell College of Medicine, New York, NY.

View Article

Download full-text PDF

Source
http://www.clinchem.org/lookup/doi/10.1373/clinchem.2018.287
Publisher Site
http://dx.doi.org/10.1373/clinchem.2018.287102DOI Listing
January 2019

Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials.

Eur Urol Oncol 2018 Nov 30. Epub 2018 Nov 30.

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2018.11.006DOI Listing
November 2018

Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC).

Br J Cancer 2018 10 22;119(9):1041-1043. Epub 2018 Oct 22.

Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41416-018-0239-y
Publisher Site
http://dx.doi.org/10.1038/s41416-018-0239-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219496PMC
October 2018

Apalutamide for the treatment of prostate cancer.

Expert Rev Anticancer Ther 2018 09;18(9):823-836

a Sidney Kimmel Center for Prostate and Urologic Cancers, Genitourinary Oncology Service, Department of Medicine , Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College , New York , NY , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2018.1503954DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6643296PMC
September 2018

Reply to C. Ren et al.

J Clin Oncol 2018 08 12;36(22):2354-2356. Epub 2018 Jun 12.

Glenn Heller, Memorial Sloan Kettering Cancer Center, New York, NY; Robert McCormack and Thian Kheoh, Janssen Research & Development, Raritan, NJ; Arturo Molina, Janssen Research & Development, Los Angeles, CA; Matthew R. Smith, Massachusetts General Hospital, Boston, MA; Robert Dreicer, University of Virginia Medical School, Charlottesville, VA; Fred Saad, University of Montreal, Montreal, Quebec, Canada; Ronald de Wit, Erasmus Medical Center, Rotterdam, Netherlands; Dana T. Aftab, Exelixis, South San Francisco, CA; Mohammed Hirmand, Medivation, San Francisco, CA; Ana Limon-Carrera, Takeda Oncology, Cambridge, MA; Karim Fizazi, Institut Gustave Roussy, Villejuif, and University of Paris Sud, Orsay, France; Martin Fleisher, Memorial Sloan Kettering Cancer Center, New York, NY; Johann S. de Bono, The Institute of Cancer Research, and The Royal Marsden Hospital, Sutton, Surrey, United Kingdom; and Howard I. Scher, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.2672DOI Listing
August 2018

A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer.

Invest New Drugs 2018 06 6;36(3):458-467. Epub 2018 Mar 6.

Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-018-0578-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6050986PMC
June 2018

Clinical implications of PTEN loss in prostate cancer.

Nat Rev Urol 2018 04 20;15(4):222-234. Epub 2018 Feb 20.

Department of Pathology, Johns Hopkins University, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrurol.2018.9
Publisher Site
http://dx.doi.org/10.1038/nrurol.2018.9DOI Listing
April 2018

Drug development for noncastrate prostate cancer in a changed therapeutic landscape.

Nat Rev Clin Oncol 2018 03 17;15(3):168-182. Epub 2017 Oct 17.

Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2017.160DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6652207PMC
March 2018

Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials.

J Clin Oncol 2018 02 22;36(6):572-580. Epub 2017 Dec 22.

Glenn Heller, Martin Fleisher, and Howard I. Scher, Memorial Sloan Kettering Cancer Center; Howard I. Scher, Weill Cornell Medical College, New York, NY; Robert McCormack, Janssen Research & Development, Raritan, NJ; Thian Kheoh and Arturo Molina, Janssen Research & Development, Los Angeles; Dana T. Aftab, Exelixis, South San Francisco; Mohammad Hirmand, Medivation, San Francisco, CA; Matthew R. Smith, Massachusetts General Hospital, Boston; Ana Limon, Takeda Oncology, Cambridge, MA; Robert Dreicer, University of Virginia Medical School, Charlottesville, VA; Fred Saad, University of Montreal, Montreal, Quebec, Canada; Ronald de Wit, Erasmus Medical Center, Rotterdam, the Netherlands; Karim Fizazi, Institut Gustave Roussy, Villejuif, and University of Paris Sud, Orsay, France; and Johann S. de Bono, The Institute of Cancer Research, and The Royal Marsden Hospital, Sutton, Surrey, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.2998DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815402PMC
February 2018

Prognostic and Predictive Value of a Breast Cancer Expression Signature in Localized Prostate Cancer.

JAMA Oncol 2017 12;3(12):1673-1674

Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2017.0750DOI Listing
December 2017

Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance.

Cancer Cell 2017 Dec 16;32(6):792-806.e7. Epub 2017 Nov 16.

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY 10065, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2017.10.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728174PMC
December 2017

A DREAM Challenge to Build Prediction Models for Short-Term Discontinuation of Docetaxel in Metastatic Castration-Resistant Prostate Cancer.

JCO Clin Cancer Inform 2017 11;1:1-15

Fatemeh Seyednasrollah and Laura L. Elo, Turku Centre for Biotechnology; University of Turku; Åbo Akademi University, Turku, Finland; Devin C. Koestler, University of Kansas Medical Center, Kansas City, KS; Tao Wang, University of Texas Southwestern Medical Center, Dallas, TX; Stephen R. Piccolo, Brigham Young University, Provo; University of Utah, Salt Lake City, Utah, UT; Roberto Vega, Russell Greiner, and Luke Kumar, University of Alberta; Alberta Innovates Centre for Machine Learning, Edmonton, Alberta, Canada; Christiane Fuchs, Helmholtz Zentrum München, Neuherberg; Technische Universität München, Garching, Germany; Eyal Gofer, The Hebrew University, Jerusalem, Israel; Russell D. Wolfinger, SAS Institute, Cary, NC; Kimberly Kanigel Winner and James C. Costello, University of Colorado, Anschutz Medical Campus, Aurora, CO; Chris Bare, Elias Chaibub Neto, Thomas Yu, Thea Norman, and Justin Guinney, Sage Bionetworks, Seattle, WA; Liji Shen and Fang Liz Zhou, Sanofi, Bridgewater, NJ; Kald Abdallah, AstraZeneca, Gaithersburg, MD; Gustavo Stolovitzky, IBM Research, Yorktown Heights; Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Howard R. Soule, Prostate Cancer Foundation, Santa Monica; Charles J. Ryan, University of California, San Francisco, CA; Christopher J. Sweeney, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Oliver Sartor, Tulane University, New Orleans, LA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/CCI.17.00018DOI Listing
November 2017

Maintaining Bone Health During Hormonal Therapy for Prostate Cancer.

Ann Intern Med 2017 09 8;167(5):357-358. Epub 2017 Aug 8.

From Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7326/M17-1800DOI Listing
September 2017

Clinical Validity of Detecting Circulating Tumor Cells by AdnaTest Assay Compared With Direct Detection of Tumor mRNA in Stabilized Whole Blood, as a Biomarker Predicting Overall Survival for Metastatic Castration-Resistant Prostate Cancer Patients.

Cancer J 2016 Sep/Oct;22(5):315-320

From the *Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; †Department of Medicine, Weill Cornell Medical College; and Departments of ‡Laboratory Medicine and §Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000220DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108569PMC
August 2017

Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

Authors:
Ahmet Zehir Ryma Benayed Ronak H Shah Aijazuddin Syed Sumit Middha Hyunjae R Kim Preethi Srinivasan Jianjiong Gao Debyani Chakravarty Sean M Devlin Matthew D Hellmann David A Barron Alison M Schram Meera Hameed Snjezana Dogan Dara S Ross Jaclyn F Hechtman Deborah F DeLair JinJuan Yao Diana L Mandelker Donavan T Cheng Raghu Chandramohan Abhinita S Mohanty Ryan N Ptashkin Gowtham Jayakumaran Meera Prasad Mustafa H Syed Anoop Balakrishnan Rema Zhen Y Liu Khedoudja Nafa Laetitia Borsu Justyna Sadowska Jacklyn Casanova Ruben Bacares Iwona J Kiecka Anna Razumova Julie B Son Lisa Stewart Tessara Baldi Kerry A Mullaney Hikmat Al-Ahmadie Efsevia Vakiani Adam A Abeshouse Alexander V Penson Philip Jonsson Niedzica Camacho Matthew T Chang Helen H Won Benjamin E Gross Ritika Kundra Zachary J Heins Hsiao-Wei Chen Sarah Phillips Hongxin Zhang Jiaojiao Wang Angelica Ochoa Jonathan Wills Michael Eubank Stacy B Thomas Stuart M Gardos Dalicia N Reales Jesse Galle Robert Durany Roy Cambria Wassim Abida Andrea Cercek Darren R Feldman Mrinal M Gounder A Ari Hakimi James J Harding Gopa Iyer Yelena Y Janjigian Emmet J Jordan Ciara M Kelly Maeve A Lowery Luc G T Morris Antonio M Omuro Nitya Raj Pedram Razavi Alexander N Shoushtari Neerav Shukla Tara E Soumerai Anna M Varghese Rona Yaeger Jonathan Coleman Bernard Bochner Gregory J Riely Leonard B Saltz Howard I Scher Paul J Sabbatini Mark E Robson David S Klimstra Barry S Taylor Jose Baselga Nikolaus Schultz David M Hyman Maria E Arcila David B Solit Marc Ladanyi Michael F Berger

Nat Med 2017 08;23(8):1004

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm0817-1004cDOI Listing
August 2017

Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone.

Clin Cancer Res 2017 Jul 17;23(14):3544-3551. Epub 2017 Feb 17.

Sidney Kimmel Center for Prostate and Urologic Cancers, Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-2509DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543693PMC
July 2017

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

Authors:
Ahmet Zehir Ryma Benayed Ronak H Shah Aijazuddin Syed Sumit Middha Hyunjae R Kim Preethi Srinivasan Jianjiong Gao Debyani Chakravarty Sean M Devlin Matthew D Hellmann David A Barron Alison M Schram Meera Hameed Snjezana Dogan Dara S Ross Jaclyn F Hechtman Deborah F DeLair JinJuan Yao Diana L Mandelker Donavan T Cheng Raghu Chandramohan Abhinita S Mohanty Ryan N Ptashkin Gowtham Jayakumaran Meera Prasad Mustafa H Syed Anoop Balakrishnan Rema Zhen Y Liu Khedoudja Nafa Laetitia Borsu Justyna Sadowska Jacklyn Casanova Ruben Bacares Iwona J Kiecka Anna Razumova Julie B Son Lisa Stewart Tessara Baldi Kerry A Mullaney Hikmat Al-Ahmadie Efsevia Vakiani Adam A Abeshouse Alexander V Penson Philip Jonsson Niedzica Camacho Matthew T Chang Helen H Won Benjamin E Gross Ritika Kundra Zachary J Heins Hsiao-Wei Chen Sarah Phillips Hongxin Zhang Jiaojiao Wang Angelica Ochoa Jonathan Wills Michael Eubank Stacy B Thomas Stuart M Gardos Dalicia N Reales Jesse Galle Robert Durany Roy Cambria Wassim Abida Andrea Cercek Darren R Feldman Mrinal M Gounder A Ari Hakimi James J Harding Gopa Iyer Yelena Y Janjigian Emmet J Jordan Ciara M Kelly Maeve A Lowery Luc G T Morris Antonio M Omuro Nitya Raj Pedram Razavi Alexander N Shoushtari Neerav Shukla Tara E Soumerai Anna M Varghese Rona Yaeger Jonathan Coleman Bernard Bochner Gregory J Riely Leonard B Saltz Howard I Scher Paul J Sabbatini Mark E Robson David S Klimstra Barry S Taylor Jose Baselga Nikolaus Schultz David M Hyman Maria E Arcila David B Solit Marc Ladanyi Michael F Berger

Nat Med 2017 Jun 8;23(6):703-713. Epub 2017 May 8.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/doifinder/10.1038/nm.4333
Publisher Site
http://dx.doi.org/10.1038/nm.4333DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461196PMC
June 2017

A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer.

Urology 2017 04 22;102:164-172. Epub 2016 Nov 22.

Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2016.10.044DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5468169PMC
April 2017

Author Reply.

Urology 2017 04 6;102:172. Epub 2017 Mar 6.

Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2016.10.046DOI Listing
April 2017

Do Patients With AR-V7-Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on Definitions.

Eur Urol 2017 01 31;71(1):4-6. Epub 2016 Aug 31.

Memorial Sloan Kettering Cancer Center, Sidney Kimmel Center for Prostate and Urologic Cancers, and Weill Cornell Medical College, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2016.08.038DOI Listing
January 2017

Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis.

Lancet Oncol 2017 01 13;18(1):143-154. Epub 2016 Dec 13.

Division of Medical Oncology, Department of Medicine, Columbia University/New York Presbyterian Hospital, Manhattan, NY, USA; James J Peters VA Medical Center, Bronx, NY, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(16)30633-7DOI Listing
January 2017

Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer.

Urol Oncol 2016 12 17;34(12):530.e15-530.e21. Epub 2016 Oct 17.

Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York, NY. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2016.07.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464417PMC
December 2016

Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor-Axis Imaging.

J Nucl Med 2016 Oct;57(Suppl 3):73S-78S

Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York; and

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.115.170134DOI Listing
October 2016

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.

N Engl J Med 2016 Aug 6;375(5):443-53. Epub 2016 Jul 6.

From the University of Washington (C.C.P., M. Beightol, C.M., B.N., H.H.C., B.M., T.W., S. Casadei, P.S.N.) and Fred Hutchinson Cancer Research Center (N.D.S., R.G., P.S.N.) - both in Seattle; the Institute of Cancer Research and Royal Marsden Hospital, London (J.M., S. Carreira, R.E., J.B.); Memorial Sloan Kettering Cancer Center (M.F.W., W.A., M. Berger, L.Z., A.Z., J. Vijai, H.I.S., C.S., N.S., P.W.K., D.S., M.R., K.O.), Weill Cornell Medical College (H.B., O.E., M.A.R.), and the Prostate Cancer Clinical Trials Consortium (J. Vinson, J.F.) - all in New York; the University of Michigan, Ann Arbor (D.R., R.L., M.H., A.C.); Howard Hughes Medical Institute, Chevy Chase, MD (A.C., C.S.); and Dana-Farber Cancer Institute, Boston (A.G., L.G., M.-E.T., S.A., G.C.H., E.M.V.A.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1603144DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986616PMC
August 2016

Small Glutamine-Rich Tetratricopeptide Repeat-Containing Protein Alpha (SGTA) Ablation Limits Offspring Viability and Growth in Mice.

Sci Rep 2016 06 30;6:28950. Epub 2016 Jun 30.

Adelaide Prostate Cancer Research Centre and Dame Roma Mitchell Cancer Research Laboratories, Faculty of Health Sciences, University of Adelaide, Adelaide, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep28950DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4928056PMC
June 2016

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

J Clin Oncol 2016 Apr 22;34(12):1402-18. Epub 2016 Feb 22.

Howard I. Scher, Michael J. Morris, Dana E. Rathkopf, and Susan F. Slovin, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College; David Nanus, NewYork Presbyterian Weill Cornell Medical Center; Lawrence W. Schwartz, NewYork Presbyterian Columbia University Medical Center, New York, NY; Walter M. Stadler, University of Chicago Medicine, Chicago, IL; Celestina Higano and Peter S. Nelson, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA; Ethan Basch, University of North Carolina at Chapel Hill, Chapel Hill, NC; Emmanual S. Antonarakis and Michael A. Carducci, Johns Hopkins University School of Medicine, Baltimore, MD; Tomasz M. Beer, Oregon Health and Science University, Portland, OR; Paul G. Corn and Christopher Logothetis, MD Anderson Cancer Center, Houston, TX; Robert Dreicer, University of Virginia School of Medicine, Charlottesville, VA; Daniel J. George, Susan Halabi, and Andrew J. Armstrong, Duke University and Duke Cancer Institute, Durham, NC; Elisabeth I. Heath, Wayne State University Karmanos Cancer Institute, Detroit; and Maha Hussain, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Wm. Kevin Kelly, Sidney Kimmel School of Medicine at Thomas Jefferson University, Philadelphia, PA; Glenn Liu and George Wilding, University of Wisconsin Carbone Cancer Center, Madison, WI; Mark N. Stein, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ; Charles S. Ryan and Eric J. Small, University of California Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Oliver Sartor, Tulane School of Medicine, New Orleans, LA; Matthew Raymond Smith, Massachusetts General Hospital Cancer Center and Harvard Medical School; Mary-Ellen Taplin and Philip W. Kantoff, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, Franc

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.2702DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872347PMC
April 2016

Defining new standards of care for men with prostate cancer.

Authors:
Howard I Scher

Lancet 2016 Mar;387(10024):1135-7

Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Sidney Kimmel Center for Prostate and Urologic Cancers, New York, NY 10065, USA; Weill Cornell Medical College, New York, NY, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(15)01235-0DOI Listing
March 2016

Reply to A. Addeo and A. Bahl.

J Clin Oncol 2016 Feb 23;34(4):387-8. Epub 2015 Nov 23.

The Institute of Cancer Research and The Royal Marsden Hospital, Sutton, Surrey, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.6562DOI Listing
February 2016

Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial.

J Clin Oncol 2016 Feb 7;34(6):557-65. Epub 2015 Dec 7.

Ethan Basch, Mark G. Kris, Howard I. Scher, Clifford A. Hudis, Paul Sabbatini, Lauren Rogak, Thomas M. Atkinson, Joanne F. Chou, Dorothy Dulko, Laura Sit, Michael Fruscione, and Deborah Schrag, Memorial Sloan Kettering Cancer Center, New York, NY; Ethan Basch, Allison M. Deal, and Antonia V. Bennett, University of North Carolina, Chapel Hill, NC; Amylou C. Dueck, Mayo Clinic, Scottsdale, AZ; Allison Barz, Children's Hospital of Philadelphia, Philadelphia, PA; Paul Novotny and Jeff A. Sloan, Mayo Clinic, Rochester, MN; and Deborah Schrag, Dana-Farber/Harvard Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.0830DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872028PMC
February 2016

CHAARTED/GETUG 12--docetaxel in non-castrate prostate cancers.

Nat Rev Clin Oncol 2015 Dec 10;12(12):687-8. Epub 2015 Nov 10.

Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2015.192DOI Listing
December 2015

Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer.

Eur Urol 2015 Nov 16;68(5):795-801. Epub 2015 Feb 16.

Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, Department of Medicine, Weill Cornell Medical College, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2015.01.026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5013546PMC
November 2015

Observed Advantages of the STAMPEDE Study Design.

Authors:
Howard I Scher

Eur Urol 2015 Jun 25;67(6):1039-1041. Epub 2014 Dec 25.

Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2014.12.004DOI Listing
June 2015

Biomarker development in the context of urologic cancers.

Urol Oncol 2015 Jun 5;33(6):295-301. Epub 2015 Mar 5.

Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2015.01.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521394PMC
June 2015

A window into new drug development for urologic oncology. Part II: Bench-to-bedside research improves survival in urologic cancer, and the discovery of better biomarkers can help predict patient response, toxicity, and resistance to therapy.

Urol Oncol 2015 Jun 26;33(6):269. Epub 2015 Mar 26.

Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2015.01.026DOI Listing
June 2015

Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors.

EJNMMI Res 2015 29;5:28. Epub 2015 Apr 29.

Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065 USA ; Department of Medicine, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10065 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13550-015-0104-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425739PMC
May 2015

Integrative clinical genomics of advanced prostate cancer.

Cell 2015 May;161(5):1215-1228

Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Urology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2015.05.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484602PMC
May 2015

Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results.

J Clin Oncol 2015 Apr 26;33(12):1356-63. Epub 2015 Jan 26.

Michael J. Morris, Steven M. Larson, and Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Arturo Molina, Thian Kheoh, Shannon L. Matheny, Vahid Naini, and Thomas W. Griffin, Janssen Research & Development, Los Angeles; Eric J. Small and Charles J. Ryan, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; Johann S. de Bono, Institute for Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom; Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Paul de Souza, University of Western Sydney School of Medicine, Ingham Institute, Liverpool, New South Wales, Australia; Philip W. Kantoff, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Celestia S. Higano, University of Washington, Seattle, WA; Jinhui Li, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski, International Drug Development Institute, Louvain-la-Neuve, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.55.3875DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881370PMC
April 2015

Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer.

J Clin Oncol 2015 Apr 23;33(12):1348-55. Epub 2015 Mar 23.

Howard I. Scher, Glenn Heller, Daniel C. Danila, and Martin Fleisher, Memorial Sloan Kettering Cancer Center; Howard I. Scher and Daniel C. Danila, Weill Cornell Medical College; Xiaoyu Jia, Columbia University, New York, NY; Arturo Molina, Janssen Research & Development, Menlo Park; Weimin Peng, Janssen Research & Development, Los Angeles; Thian Kheoh, Janssen Research & Development, San Diego, CA; Gerhardt Attard, Shahneen K. Sandhu, David Olmos, Ruth Riisnaes, and Johann S. de Bono, Institute of Cancer Research; Gerhardt Attard, Shahneen K. Sandhu, David Olmos, and Johann S. de Bono, Royal Marsden Hospital, Sutton, United Kingdom; Robert McCormack, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski and Marc Buyse, International Drug Development Institute, Louvain-la-Neuve, Belgium.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/03/23/JCO.2014.55
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.55.3487
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.55.3487DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397279PMC
April 2015

A window into new drug development for urologic oncology. Part I: How bench-to-bedside research can result in approval.

Urol Oncol 2015 Mar 22;33(3):115. Epub 2015 Jan 22.

Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2014.12.004DOI Listing
March 2015

Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial.

Eur Urol 2015 Feb 27;67(2):223-30. Epub 2014 Aug 27.

Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2014.08.025DOI Listing
February 2015

Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.

Cancer Cell 2015 Jan 24;27(1):109-22. Epub 2014 Dec 24.

Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medical College, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2014.11.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293347PMC
January 2015

Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.

J Clin Oncol 2014 Oct 15;32(30):3391-9. Epub 2014 Sep 15.

Matthew R. Smith, Massachusettes General Hospital; Christopher J. Sweeney, Aymen Elfiky, Dana-Farber Cancer Institute, Boston, MA; Paul G. Corn, Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Dana E. Rathkopf, Howard I. Scher, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY; David C. Smith, Maha Hussain, University of Michigan, Ann Arbor, MI; Daniel J. George, Duke University Medical Center, Durham; Ethan M. Basch, University of North Carolina, Chapel Hill, NC; Celestia S. Higano, University of Washington, Seattle, WA; Andrea L. Harzstark, University of California San Francisco, San Francisco; Christian Scheffold, A. Douglas Laird, Frauke Schimmoller, Exelixis, South San Francisco, CA; A. Oliver Sartor, Tulane Cancer Center, Tulane University, New Orleans, LA; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ; Naomi B. Haas, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Johann S. de Bono, Royal Marsden Hospital, Sutton, Surrey, United Kingdom.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2014/09/15/JCO.2013.54
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2013.54.5954
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.54.5954DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383838PMC
October 2014

Organoid cultures derived from patients with advanced prostate cancer.

Cell 2014 Sep 4;159(1):176-187. Epub 2014 Sep 4.

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Medicine, Weill Cornell Medical College and New York-Presbyterian Hospital, New York, NY 10065, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2014.08.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237931PMC
September 2014